1,584 results on '"Fung JJ"'
Search Results
2. Allotrapianto di insule pancreatiche: sei anni di esperienza all’ Università di Pittsburgh
- Author
-
Rastellini C., Cicalese L., Shapiro R., Sileri P, Corry R., Ferrari D., Fung JJ., Rao AS., Ricordi C., Starzl TE., Rastellini, C., Cicalese, L., Shapiro, R., Sileri, P, Corry, R., Ferrari, D., Fung, Jj., Rao, As., Ricordi, C., and Starzl, Te.
- Published
- 1998
3. TIPS in liver transplant candidates
- Author
-
Bartoli FA, ALDRIGHETTI L, Jabbour N, Zajko AB, Leggio A., Fung JJ, Bartoli, Fa, Aldrighetti, L, Jabbour, N, Zajko, Ab, Leggio, A., and Fung, Jj
- Published
- 1996
4. Effect of donor age and sex on the outcome of liver transplantation
- Author
-
Marino IR, Doyle HR, Aldrighetti L, Doria C, McMichael J, Gayowski T, Fung JJ, Tzakis AG, Starzl TE, RI Fung John/A-2679-2012, Marino, Ir, Doyle, Hr, Aldrighetti, L, Doria, C, Mcmichael, J, Gayowski, T, Fung, Jj, Tzakis, Ag, Starzl, Te, and RI Fung, John/A-2679-2012
- Abstract
We correlated donor and recipient factors with graft outcome in 436 adult patients who underwent 462 liver transplants. Donor variables analyzed were age, gender, ABO blood group, cause of death, length of stay in the intensive care unit, use of pressors or pitressin, need for cardiopulmonary resuscitation, terminal serum transaminases, and ischemia time. Recipient variables analyzed were age, gender, primary diagnosis, history of previous liver transplant, ABO blood group, cytotoxic antibody crossmatch, United Network for Organ Sharing (UNOS) status, and waiting time (except for the cross-match results, they were all known at the time of the operation). The endpoint of the analysis was graft failure, defined as patient death or retransplantation. Using multivariate analysis, graft failure was significantly associated with donor age, donor gender, previous liver transplantation, and UNOS 4 status of the recipient. The effect of donor age became evident only when they were older than 45 years. Livers horn female donors yielded significantly poorer results, with a-year graft survival of female to male 55% (95% CI, 45% to 67%); female to female, 64% (95% CI, 54% to 77%); male to male, 72% (95% CI, 66% to 78%); and male to female, 78% (95% CI, 70% to 88%). The only donors identified as questionable for liver procurement were old (greater than or equal to 60 years) women in whom the adverse age and gender factors were at least additive. However, rather than discard even these livers, in the face of an organ shortage crisis, their individualized use is suggested with case reporting in a special category.
- Published
- 1995
5. La TIPS nel trattamento dell'ipertensione portale intraepatica in candidati al trapianto epatico
- Author
-
Bartoli FA, Leggio A, ALDRIGHETTI L, Zajko AB, Fung JJ, Bartoli, Fa, Leggio, A, Aldrighetti, L, Zajko, Ab, and Fung, Jj
- Published
- 1995
6. OUTCOME OF LIVER-TRANSPLANTATION USING DONORS 60 TO 79 YEARS OF AGE
- Author
-
MARINO IR, DOYLE HR, DORIA C, ALDRIGHETTI L, GAYOWSKI T, SCOTTIFOGLIENI C, FURUKAWA H, FUNG JJ, TZAKIS AG, STARZL TE, Marino, Ir, Doyle, Hr, Doria, C, Aldrighetti, L, Gayowski, T, Scottifoglieni, C, Furukawa, H, Fung, Jj, Tzakis, Ag, and Starzl, Te
- Published
- 1995
7. Long term results after transjugular intrahepatic portosystemic shunt (TIPS)
- Author
-
Jabbour N, Marsh JW, Irish W, Zajko AB, Orons PH, ALDRIGHETTI L, Bartoli F, Colangelo J, Iwatsuki J, Rakela J, Fung JJ, Jabbour, N, Marsh, Jw, Irish, W, Zajko, Ab, Orons, Ph, Aldrighetti, L, Bartoli, F, Colangelo, J, Iwatsuki, J, Rakela, J, and Fung, Jj
- Published
- 1995
8. Breaking the donor age barrier to face the organ shortage in liver transplantation
- Author
-
ALDRIGHETTI L, Marino IR, Doyle HR, Doria C, Scotti-Foglieni C, Kovalak J, Fung JJ, Tzakis AG, Starzl TE, Aldrighetti, L, Marino, Ir, Doyle, Hr, Doria, C, Scotti-Foglieni, C, Kovalak, J, Fung, Jj, Tzakis, Ag, and Starzl, Te
- Published
- 1994
9. SCREENING FOR HEPATOMA IN CIRRHOTICS DURING LIVER-TRANSPLANT (OLTX) EVALUATION - COMPARISON OF STANDARD SCREENING METHODS, STATISTICAL-MODELS, AND ARTIFICIAL NEURAL NETWORKS
- Author
-
DOYLE HR, PARMANTO B, MARINO IR, MUNRO PW, ALDRIGHETTI L, DORIA C, MCMICHAEL J, FUNG JJ, Doyle, Hr, Parmanto, B, Marino, Ir, Munro, Pw, Aldrighetti, L, Doria, C, Mcmichael, J, and Fung, Jj
- Published
- 1994
10. Liver transplantation outcome using donors 60 to 79 years of age
- Author
-
Marino IR, Doyle HR, Doria C, ALDRIGHETTI L, Gayowsky T, Fung JJ, Tzakis AG, Starzl TE, Marino, Ir, Doyle, Hr, Doria, C, Aldrighetti, L, Gayowsky, T, Fung, Jj, Tzakis, Ag, and Starzl, Te
- Published
- 1994
11. Neural Network Classifier for hepatoma detection
- Author
-
Parmanto B, Munro PW, Doyle HR, Doria C, ALDRIGHETTI L, Marino IR, Mitchel S, Fung JJ, Parmanto, B, Munro, Pw, Doyle, Hr, Doria, C, Aldrighetti, L, Marino, Ir, Mitchel, S, and Fung, Jj
- Published
- 1994
12. Themes of liver transplantation
- Author
-
Starzl, TE, Fung, JJ, Starzl, TE, and Fung, JJ
- Abstract
Liver transplantation was the product of five interlocking themes. These began in 1958-1959 with canine studies of then theoretical hepatotrophic molecules in portal venous blood (Theme I) and with the contemporaneous parallel development of liver and multivisceral transplant models (Theme II). Further Theme I investigations showed that insulin was the principal, although not the only, portal hepatotrophic factor. In addition to resolving long-standing controversies about the pathophysiology of portacaval shunt, the hepatotrophic studies blazed new trails in the regulation of liver size, function, and regeneration. They also targeted inborn metabolic errors (e.g., familial hyperlipoproteinemia) whose palliation by portal diversion presaged definitive correction with liver replacement. Clinical use of the Theme II transplant models depended on multiple drug immunosuppression (Theme III, Immunology), guided by an empirical algorithm of pattern recognition and therapeutic response. Successful liver replacement was first accomplished in 1967 with azathioprine, prednisone, and antilymphoid globulin. With this regimen, the world's longest surviving liver recipient is now 40 years postoperative. Incremental improvements in survival outcome occurred (Theme IV) when azathioprine was replaced by cyclosporine (1979), which was replaced in turn by tacrolimus (1989). However, the biologic meaning of alloengraftment remained enigmatic until multilineage donor leukocyte microchimerism was discovered in 1992 in long-surviving organ recipients. Seminal mechanisms were then identified (clonal exhaustion-deletion and immune ignorance) that linked organ engraftment and the acquired tolerance of bone marrow transplantation and eventually clarified the relationship of transplantation immunology to the immunology of infections, neoplasms, and autoimmune disorders. With this insight, better strategies of immunosuppression have evolved. As liver and other kinds of organ transplantation beca
- Published
- 2010
13. Reconstruction of an abnormal hepatic vein in a donor liver - A case report
- Author
-
Felekouras, ES Tsamandas, AC Papalampros, EL Pikoulis, EA and Leppaniemi, AK Fung, JJ
- Subjects
surgical procedures, operative - Abstract
In the era of worldwide organ shortage for liver transplantation, every effort must be made to use all potentially available livers. In this case report, we present a liver graft with abnormal left hepatic vein draining directly to the right atrium of the donor heart, which was discovered during back table preparation of a liver graft. The vein was reconstructed and the subsequent liver transplantation was successful. Five years after the transplantation, no signs of complications have emerged.
- Published
- 1998
14. World's longest surviving liver-pancreas recipient
- Author
-
Harary, AM, Abu-Eimagd, K, Thai, N, Shapiro, R, Todo, S, Fung, JJ, Starzl, TE, Harary, AM, Abu-Eimagd, K, Thai, N, Shapiro, R, Todo, S, Fung, JJ, and Starzl, TE
- Abstract
In July 1988, the liver and pancreas of a cadaveric donor were transplanted separately into a man with type 1 diabetes with end-stage chronic hepatitis B virus. Two features of the operation may help explain the patient's current status as the longest-lived liver-pancreas recipient. One was enteric drainage of pancreatic exocrine secretions. The other was delivery of the pancreas venous effluent to the host portal system and then directly to the hepatic allograft. © 2007 AASLD.
- Published
- 2007
15. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes
- Author
-
Thai, NL, Khan, A, Tom, K, Blisard, D, Basu, A, Tan, HP, Marcos, A, Fung, JJ, Starzl, TE, Shapiro, R, Thai, NL, Khan, A, Tom, K, Blisard, D, Basu, A, Tan, HP, Marcos, A, Fung, JJ, Starzl, TE, and Shapiro, R
- Abstract
BACKGROUND. Alemtuzumab (Campath-1H) induction with tacrolimus monotherapy has been shown to provide effective immunosuppression for kidney, liver, lung, and small bowel transplantation. This drug combination was evaluated in pancreas transplant recipients. METHODS. Sixty consecutive pancreas transplants (30 simultaneous pancreas-kidney, 20 pancreas after kidney, and 10 pancreas alone) were carried out under this protocol between July 2003 to January 2005. The mean follow-up was 22 months (range 17-33). RESULTS. One-year patient, pancreas, and kidney allograft survival were 95%, 93%, and 90%, respectively. With 22 months follow-up, patient, pancreas, and kidney survival were 94%, 89%, and 87%, respectively. The rejection rate was 30% (18/60), with four patients (7%) experiencing steroid-resistant rejection. Major infection occurred in three (5%) patients resulting in two (3.3%) deaths from disseminated histoplasmosis and a herpes virus infection. One patient with cryptococcal meningitis was successfully treated. Seven (11.7%) patients experienced cytomegalovirus infection, all of whom responded to treatment with ganciclovir. One (1.7%) case of polymorphic posttransplant lymphoproliferative disease was seen, which regressed with a temporary discontinuation of tacrolimus and high-dose ganciclovir. The mean serum creatinine of the 30 simultaneous pancreas-kidney transplants at one year posttransplant was 1.37±0.33 mg/ml. The preexisting creatinine in pancreas after kidney transplants was not adversely affected by this immunosuppressive protocol. CONCLUSION. A single dose of perioperative alemtuzumab followed by daily tacrolimus monotherapy provides effective immunosuppression for pancreas transplantation, but the optimal use of this drug combination is not yet clear. © 2006 Lippincott Williams & Wilkins, Inc.
- Published
- 2006
16. Immunosuppression for liver transplantation in HCV-infected patients: Mechanism-based principles
- Author
-
Eghtesad, B, Fung, JJ, Demetris, AJ, Murase, N, Ness, R, Bass, DC, Gray, EA, Shakil, O, Flynn, B, Marcos, A, Starzl, TE, Eghtesad, B, Fung, JJ, Demetris, AJ, Murase, N, Ness, R, Bass, DC, Gray, EA, Shakil, O, Flynn, B, Marcos, A, and Starzl, TE
- Abstract
We retrospectively analyzed 42 hepatitis C virus (HCV)-infected patients who underwent cadaveric liver transplantation under two strategies of immunosuppression: (1) daily tacrolimus (TAC) throughout and an initial cycle of high-dose prednisone (PRED) with subsequent gradual steroid weaning, or (2) intraoperative antithymocyte globulin (ATG) and daily TAC that was later space weaned. After 36 ± 4 months, patient and graft survival in the first group was 18/19 (94.7%) with no examples of clinically serious HCV recurrence. In the second group, the three-year patient survival was 12/23 (52%), and graft survival was 9/23 (39%); accelerated recurrent hepatitis was the principal cause of the poor results. The data were interpreted in the context of a recently proposed immunologic paradigm that is equally applicable to transplantation and viral immunity. In the framework of this paradigm, the disparate hepatitis outcomes reflected different equilibria reached under the two immunosuppression regimens between the relative kinetics of viral distribution (systemically and in the liver) and the slowly recovering HCV-specific T-cell response. As a corollary, the aims of treatment of the HCV-infected liver recipients should be to predict, monitor, and equilibrate beneficial balances between virus distribution and the absence of an immunopathologic antiviral T-cell response. In this view, favorable equilibria were accomplished in the nonweaned group of patients but not in the weaned group. In conclusion, since the anti-HCV response is unleashed when immunosuppression is weaned, treatment protocols that minimize disease recurrence in HCV-infected allograft recipients must balance the desire to reduce immunosuppression or induce allotolerance with the need to prevent antiviral immunopathology. Copyright © 2005 by the American Association for the Study of Liver Diseases.
- Published
- 2005
17. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath
- Author
-
Shapiro, R, Basu, A, Tan, H, Gray, E, Kahn, A, Randhawa, P, Murase, N, Zeevi, A, Girnita, A, Metes, D, Ness, R, Bass, DC, Demetris, AJ, Fung, JJ, Marcos, A, Starzl, TE, Shapiro, R, Basu, A, Tan, H, Gray, E, Kahn, A, Randhawa, P, Murase, N, Zeevi, A, Girnita, A, Metes, D, Ness, R, Bass, DC, Demetris, AJ, Fung, JJ, Marcos, A, and Starzl, TE
- Abstract
BACKGROUND: Multiple drug immunosuppression has allowed the near elimination of rejection, but without commensurate improvements in longterm graft survival and at the cost of quality of life. We have suggested that transplantation outcomes can be improved by modifying the timing and dosage of immunosuppression to facilitate natural mechanisms of alloengraftment and acquired tolerance. STUDY DESIGN: Two therapeutic principles were applied for kidney transplantation: pretransplant recipient conditioning with antilymphoid antibody preparations (Thymoglobulin [Sangstat] or Campath [ILEX Pharmaceuticals]), and minimal posttransplant immunosuppression with tacrolimus monotherapy including "spaced weaning" of maintenance doses when possible. The results in Thymoglobulin- (n = 101) and Campath-pretreated renal transplantation recipients (n = 90) were compared with those in 152 conventionally immunosuppressed recipients in the immediately preceding era. RESULTS: Spaced weaning was attempted in more than 90% of the kidney transplant recipients after pretreatment with both lymphoid-depleting agents, and is currently in effect in two-thirds of the survivors. Although there was a much higher rate of acute rejection in the Thymoglobulin-pretreated recipients than in either the Campath-pretreated or historic control recipients, patient and graft survival in both lymphoid depletion groups is at least equivalent to that of historic control patients. In the Thymoglobulin-conditioned patients for whom followups are now 24 to 40 months, chronic allograft nephropathy (CAN) progressed at the same rate as in historic control patients. Selected patients on weaning developed donor-specific nonreactivity. CONCLUSIONS: After lymphoid depletion, kidney transplantation can be readily accomplished under minimal immunosuppression with less dependence on late maintenance immunosuppression and a better quality of life. Campath was the more effective agent for pretreatment. Guidelines for spaced wea
- Published
- 2005
18. History of Liver and Multivisceral Transplantation
- Author
-
Starzl, TE, Murase, N, Marcos, A, Fung, JJ, Starzl, TE, Murase, N, Marcos, A, and Fung, JJ
- Published
- 2005
19. Clinical use of immunosuppressants
- Author
-
Fink, M, Abraham, E, Vincent, JL, Kochanek, P, Schonder, KS, Weber, RJ, Fung, JJ, Starzl, TE, Fink, M, Abraham, E, Vincent, JL, Kochanek, P, Schonder, KS, Weber, RJ, Fung, JJ, and Starzl, TE
- Published
- 2005
20. Cell Migration, Chimerism, and Graft Acceptance, with Particular Reference to the Liver
- Author
-
Starzl, TE, Murase, N, Demetris, AJ, Trucco, M, Eghtesad, B, Fontes, P, Abu-Elmagd, K, Marcos, A, Fung, JJ, Starzl, TE, Murase, N, Demetris, AJ, Trucco, M, Eghtesad, B, Fontes, P, Abu-Elmagd, K, Marcos, A, and Fung, JJ
- Published
- 2005
21. Recurrent Hepatitis C in Liver Allografts: Prospective Assessment of Diagnostic Accuracy, Identification of Pitfalls, and Observations about Pathogenesis
- Author
-
Demetris, AJ, Eghtesad, B, Marcos, A, Ruppert, K, Nalesnik, MA, Randhawa, P, Wu, T, Krasinskas, A, Fontes, P, Cacciarelli, T, Shakil, AO, Murase, N, Fung, JJ, Starzl, TE, Demetris, AJ, Eghtesad, B, Marcos, A, Ruppert, K, Nalesnik, MA, Randhawa, P, Wu, T, Krasinskas, A, Fontes, P, Cacciarelli, T, Shakil, AO, Murase, N, Fung, JJ, and Starzl, TE
- Abstract
Rationale and Design: The accuracy of a prospective histopathologic diagnosis of rejection and recurrent hepatitis C (HCV) was determined in 48 HCV RNA-positive liver allograft recipients enrolled in an "immunosuppression minimization protocol" between July 29, 2001 and January 24, 2003. Prospective entry of all pertinent treatment, laboratory, and histopathology results into an electronic data-base enabled a retrospective analysis of the accuracy of histopathologic diagnoses and the pathophysiologic relationship between recurrent HCV and rejection. Results: Time to first onset of acute rejection (AR) (mean, 107 days; median, 83 days; range, 7-329 days) overlapped with the time to first onset of recurrent HCV (mean, 115 days; median, 123 days; range, 22-315 days), making distinction between the two difficult. AR and chronic rejection (CR) with and without co-existent HCV showed overlapping but significantly different liver injury test profiles. One major and two minor errors occurred (positive predictive values for AR = 91%; recurrent HCV = 100%) ; all involved an overdiagnosis of AR in the context of recurrent HCV. Retrospective analysis of the mistakes showed that major errors can be avoided altogether and the impact of unavoidable minor errors can be minimized by strict adherence to specific histopathologic criteria, close clinicopathologic correlation including examination of HCV RNA levels, and a conservative approach to the use of additional immunosuppression. In addition, histopathologic diagnoses of moderate and severe AR and CR were associated with relatively low HCV RNA levels, whereas relatively high HCV RNA levels were associated with a histopathologic diagnosis of hepatitis alone, particularly the cholestatic variant of HCV. Conclusions: Liver allograft biopsy interpretation can rapidly and accurately distinguish between recurrent HCV and AR/CR. In addition, the histopathologic observations suggest that the immune mechanism responsible for HCV clearance
- Published
- 2004
22. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: A single canter preliminary experience
- Author
-
Tan, HP, Kaczorowski, DJ, Basu, A, Khan, A, McCauley, J, Marcos, A, Fung, JJ, Starzl, TE, Shapiro, R, Tan, HP, Kaczorowski, DJ, Basu, A, Khan, A, McCauley, J, Marcos, A, Fung, JJ, Starzl, TE, and Shapiro, R
- Abstract
Background. End-stage renal disease (ESRD) is an increasing problem in patients infected with the human immunodeficiency virus (HIV). The use of highly active antiretroviral therapy (HAART) has decreased the morbidity associated with HIV and has prompted renewed interest in renal transplantation. Methods. We performed four cases of deceased donor renal transplantation in HIV+ recipients and three cases where laparoscopic live donor nephrectomy (LLDN) was utilized to obtain the kidney for transplantation into living-related HIV+ recipients. In the four deceased donor cases, conventional tacrolimus-based immunosuppression, without antibody induction was used. In the three living-related cases, the immunosuppressive regimen was based on two principles: recipient pretreatment and minimal posttransplant immunosuppression. Alemtuzumab 30 mg (Campath 1-H) was used for preconditioning followed by low-dose tacrolimus monotherapy. Results. Of the four deceased donor cases, one patient continues to have good graft function, and another is not yet on dialysis but has significant graft dysfunction. Rejection was observed in three patients (75%). Infectious complications occurred in one patient (25%), all non-acquired immunodeficiency syndrome (AIDs) defining. In the three living-related cases, all had good graft function, and none have experienced acute rejection. HIV viral loads remain undetectable. CD4 counts are slowly recovering. No infectious or surgical complications occurred. There were no deaths in either group. Conclusions. These data suggest that living-related donor renal transplantation with steroid-free tacrolimus monotherapy in a "tolerogenic" regimen can be efficacious. However, long-term follow-up is needed to confirm this observation.
- Published
- 2004
23. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation
- Author
-
Keven, K, Basu, A, Re, L, Tan, H, Marcos, A, Fung, JJ, Starzl, TE, Simmons, RL, Shapiro, R, Keven, K, Basu, A, Re, L, Tan, H, Marcos, A, Fung, JJ, Starzl, TE, Simmons, RL, and Shapiro, R
- Published
- 2004
24. Lessons of organ-induced tolerance learned from historical clinical experience
- Author
-
Starzl, TE, Murase, N, Demetris, AJ, Trucco, M, Abu-Elmagd, K, Gray, EA, Eghtesad, B, Shapiro, R, Marcos, A, Fung, JJ, Starzl, TE, Murase, N, Demetris, AJ, Trucco, M, Abu-Elmagd, K, Gray, EA, Eghtesad, B, Shapiro, R, Marcos, A, and Fung, JJ
- Abstract
Although the reductionist approach has served science well for 400 years, the accumulation of details can obscure the truth if the original premise is incorrect. One such premise has been that successful organ transplantation and bone marrow engraftment are fundamentally different outcomes involving separate and distinct mechanisms. Some historical clinical observations pointed to a different conclusion almost from the beginning and included clues about how to induce tolerance with the aid of immunosuppression.
- Published
- 2004
25. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: With particular reference to hepatitis C virus
- Author
-
Marcos, A, Eghtesad, B, Fung, JJ, Fontes, P, Patel, K, DeVera, M, Marsh, W, Gayowski, T, Demetris, AJ, Gray, EA, Flynn, B, Zeevi, A, Murase, N, Starzl, TE, Marcos, A, Eghtesad, B, Fung, JJ, Fontes, P, Patel, K, DeVera, M, Marsh, W, Gayowski, T, Demetris, AJ, Gray, EA, Flynn, B, Zeevi, A, Murase, N, and Starzl, TE
- Abstract
We have proposed that the mechanisms of alloengraftment and variable acquired tolerance can be facilitated by minimum posttransplant immunosuppression. It was further suggested that the efficacy of minimalistic treatment could be enhanced by preoperative recipient conditioning with an antilymphoid antibody preparation. A total of 76 adults (38 hepatitis C virus [HCV]-, 38 HCV+ were infused with 30 mg alemtuzumab before primary cadaveric liver transplantation and maintained afterward on daily monotherapy unless breakthrough rejection mandated additional agents. In stable patients, the intervals between tacrolimus doses were lengthened ("spaced weaning") after approximately 4 months. Eighty-four contemporaneous nonlymphoid-depleted liver recipients (58 HCV-, 26 HCV+) were treated with conventional postoperative immunosuppression. The overall incidence of rejection was similar with the two strategies of immunosuppression. With follow-ups of 14 to 22 months, patient and primary graft survival in HCV- cases are 97% and 90%, respectively, with alemtuzumab depletion plus minimal immunosuppression versus 71% and 70%, respectively, under conventional immunosuppression. In HCV+ recipients, current patient and graft survival in the alemtuzumab-pretreated group are 71% and 70% versus 65% and 54%, respectively, under conventional treatment. With both strategies of immunosuppression, the adverse effect of preexisting HCV on survival parameters and graft function already was significant at the 1-year milestone, but its extent was not evident until the second year. With or without HCV, 62% of the 64 surviving lymphoid-depleted patients are on spaced immunosuppression, and four patients receive no immunosuppression. Lymphoid depletion with alemtuzumab and minimalistic maintenance immunosuppression is a practical strategy of liver transplantation in HCV- recipients but not HCV+ recipients.
- Published
- 2004
26. Tolerogenic immunosuppression for organ transplantation
- Author
-
Starzl, TE, Murase, N, Abu-Elmagd, K, Gray, EA, Shapiro, R, Eghtesad, B, Corry, RJ, Jordan, ML, Fontes, P, Gayowski, T, Bond, G, Scantlebury, VP, Potdar, S, Randhawa, P, Wu, T, Zeevi, A, Nalesnik, MA, Woodward, J, Marcos, A, Trucco, M, Demetris, AJ, Fung, JJ, Starzl, TE, Murase, N, Abu-Elmagd, K, Gray, EA, Shapiro, R, Eghtesad, B, Corry, RJ, Jordan, ML, Fontes, P, Gayowski, T, Bond, G, Scantlebury, VP, Potdar, S, Randhawa, P, Wu, T, Zeevi, A, Nalesnik, MA, Woodward, J, Marcos, A, Trucco, M, Demetris, AJ, and Fung, JJ
- Abstract
Background: Insight into the mechanisms of organ engraftment and acquired tolerance has made it possible to facilitate these mechanisms, by tailoring the timing and dosage of immunosuppression in accordance with two therapeutic principles: recipient pretreatment, and minimum use of post-transplant immunosuppression. We aimed to apply these principles in recipients of renal and extrarenal organ transplants. Methods: 82 patients awaiting kidney, liver, pancreas, or intestinal transplantation were pretreated with about 5 mg/kg of a broadly reacting rabbit antithymocyte globulin during several hours. Post-transplant immunosuppression was restricted to tacrolimus unless additional drugs were needed to treat breakthrough rejection. After 4 months, patients on tacrolimus monotherapy were considered for dose-spacing to every other day or longer intervals. Findings: We frequently saw evidence of immune activation in graft biopsy samples, but unless this was associated with graft dysfunction or serious immune destruction, treatment usually was not intensified. Immunosuppression-related morbidity was virtually eliminated. 78 (95%) of 82 patients survived at 1 year and at 13-18 months. Graft survival was 73 (89%) of 82 at 1 year and 72 (88%) of 82 at 13-18 months. Of the 72 recipients with surviving grafts, 43 are on spaced doses of tacrolimus monotherapy: every other day (n=6), three times per week (11), twice per week (15), or once per week (11). Interpretation: The striking ability to wean immunosuppression in these recipients indicates variable induction of tolerance. The simple therapeutic principles are neither drug-specific nor organ-specific. Systematic application of these principles should allow improvements in quality of life and long-term survival after organ transplantation.
- Published
- 2003
27. Kidney Transplantation under a Tolerogenic Regimen of Recipient Pretreatment and Low-Dose Postoperative Immunosuppression with Subsequent Weaning
- Author
-
Shapiro, R, Jordan, ML, Basu, A, Scantlebury, V, Potdar, S, Tan, HP, Gray, EA, Randhawa, PS, Murase, N, Zeevi, A, Demetris, AJ, Woodward, J, Marcos, A, Fung, JJ, Starzl, TE, Najarian, JS, Schulak, JA, Shapiro, R, Jordan, ML, Basu, A, Scantlebury, V, Potdar, S, Tan, HP, Gray, EA, Randhawa, PS, Murase, N, Zeevi, A, Demetris, AJ, Woodward, J, Marcos, A, Fung, JJ, Starzl, TE, Najarian, JS, and Schulak, JA
- Abstract
Objective: The purpose of this work was to perform kidney transplantation under a regimen of immunosuppression that facilitates rather than interferes with the recently defined mechanisms of alloengraftment and acquired tolerance. Summary Background Data: In almost all centers, multiple immunosuppressive agents are given in large doses after kidney transplantation in an attempt to reduce the incidence of acute rejection to near zero. With the elucidation of the mechanisms of alloengraftment and acquired tolerance, it was realized that such heavy prophylactic immunosuppression could systematically subvert the clonal exhaustion-deletion that is the seminal mechanism of tolerance. In addition, it has been established that the rejection response can be made more readily treatable by pretransplant immunosuppression. Consequently, we conducted kidney transplantation in compliance with 2 therapeutic principles: recipient pretreatment and the least possible use of posttransplant immunosuppression. Methods: One-hundred fifty unselected renal transplant recipients with a mean age of 51 ± 15 years and multiple risk factors had pretreatment with approximately 5 mg/kg of rabbit antithymocyte globulin (Thymoglobulin) in the hours before transplantation, under covering bolus doses of prednisone to prevent cytokine reactions. Minimal posttransplant immunosuppression was with tacrolimus monotherapy to which steroids or other agents were added only for the treatment of rejection. At or after 4 months after transplant, spaced-dose weaning from tacrolimus monotherapy was begun in patients who had exhibited a satisfactory course. Results: One-year actuarial patient and graft survival was 97% and 92%, respectively. Although the incidence of early acute rejection was 37%, only 7% required prolonged treatment with any agent other than tacrolimus. After a follow-up of 6 to 21 months, the mean serum creatinine in patients with functioning grafts is 1.8 ± 1.0 mg/dL. Seventy-three percent of t
- Published
- 2003
28. Pregnancy after liver transplantation with tacrolimus immunosuppression: A single center's experience update at 13 years
- Author
-
Jain, AB, Reyes, J, Marcos, A, Mazariegos, G, Eghtesad, B, Fontes, PA, Cacciarelli, TV, Marsh, JW, De Vera, ME, Rafail, A, Starzl, TE, Fung, JJ, Jain, AB, Reyes, J, Marcos, A, Mazariegos, G, Eghtesad, B, Fontes, PA, Cacciarelli, TV, Marsh, JW, De Vera, ME, Rafail, A, Starzl, TE, and Fung, JJ
- Abstract
Background. Chronic liver disease often leads to amenorrhea in women of childbearing age. There are several reports of successful pregnancy after liver transplantation (LTx) with cyclosporine A immunosuppression. Tacrolimus has been increasingly used in solid-organ transplantation, and the effect of the drug on pregnancy is still of interest to clinicians. This study updates our single-center experience. Methods. All pregnancies after LTx with tacrolimus immunosuppression were followed prospectively. Patients' clinical courses during pregnancy and labor along with gestational period and birth weight were catalogued. Changes in liver function, renal function, and immunosuppression also were recorded. The birth weight percentile was calculated on the basis of the gestational period using a standard chart. Results. Thirty-seven mothers delivered 49 babies. Three mothers delivered three times, and six mothers delivered two times. Thirty-six mothers (97%) survived the pregnancy, and 36 allografts (97%) survived. The one death and graft loss was in a patient who demonstrated infra-aortic arterial graft, which clotted by the gravid uterus during labor. The patient developed a gangrenous liver and died before she could undergo retransplantation. The mean gestational period was 36.4±3. 2 weeks, excluding two premature deliveries at 23 and 24 weeks gestation. Twenty-two babies (46.9%) were delivered by cesarean section, and the other babies were delivered vaginally. In addition to the two premature babies, one baby, who was born to a mother with Alagille syndrome, died from congenital birth defects. The rest of the newborns survived. The mean birth weight was 2,797±775 g, with 38 babies (78%) weighing more than 2,000 g. The mean birth weight percentile to gestational period was 54±23. Four babies (8.5%) had a birth weight percentile of less than 25, and 28 babies (59.6%) had a birth weight percentile greater than 50. Twelve patients demonstrated an increase in hepatic enzymes
- Published
- 2003
29. Four-color flow cytometric analysis of peripheral blood donor cell chimerism
- Author
-
Metes, D, Logar, A, Rudert, WA, Zeevi, A, Woodward, J, Demetris, AJ, Abu-Elmagd, K, Eghtesad, B, Shapiro, R, Fung, JJ, Trucco, M, Starzl, TE, Murase, N, Metes, D, Logar, A, Rudert, WA, Zeevi, A, Woodward, J, Demetris, AJ, Abu-Elmagd, K, Eghtesad, B, Shapiro, R, Fung, JJ, Trucco, M, Starzl, TE, and Murase, N
- Abstract
Passenger leukocytes have been demonstrated to play significant roles in initiating and also regulating immune reactions after organ transplantation. Reliable techniques to detect donor leukocytes in recipients after organ transplantation are essential to analyze the role, function, and behavior of these leukocytes. In this report we describe a simple, reliable method to detect donor cells with low frequencies using peripheral blood samples. Detection of small numbers of major histocompatibility complex (MHC) mismatched cells was first studied using four-color flow cytometry in artificially created cell mixtures. By selecting the CD45+ population and simultaneous staining with several leukocyte lineage markers (CD3, CD4, CD8, CD56, and CD19), MHC-mismatched leukocytes were consistently detected in cell suspensions prepared from directly stained whole blood samples with a threshold sensitivity as low as 0.1%-0.2%. When the fresh peripheral blood mononuclear cells were separated by conventional Ficoll gradient purification, similar, but slightly lower levels of donor cells were detected. Blood samples obtained 1-5 months after liver, kidney, and intestine transplants revealed that the kind of organ allograft influenced levels and lineage pattern of the circulating donor cells. This procedure provided a simple and reliable method in determining early chimerism in transplant recipients. However, the detection of MHC-mismatched leukocytes of all lineages was much lower when frozen peripheral blood mononuclear cells were used. © American Society for Histocompatibility and Immunogenetics, 2003. Published by Elsevier Inc.
- Published
- 2003
30. Portacaval shunt causes apoptosis and liver atrophy in rats despite increases in endogenous levels of major hepatic growth factors
- Author
-
Gandhi, CR, Murase, N, Subbotin, VM, Uemura, T, Nalesnik, M, Demetris, AJ, Fung, JJ, Starzl, TE, Gandhi, CR, Murase, N, Subbotin, VM, Uemura, T, Nalesnik, M, Demetris, AJ, Fung, JJ, and Starzl, TE
- Abstract
Background/Aims: The response to the liver damage caused by portacaval shunt (PCS) is characterized by low-grade hyperplasia and atrophy. To clarify mechanisms of this dissociation, we correlated the expression of 'hepatotrophic factors' and the antihepatotrophic and proapoptotic peptide, transforming growth factor (TGF)-β, with the pathologic changes caused by PCS in rats. Methods: PCS was created by side-to-side anastomosis between the portal vein and inferior vena cava, with ligation of the hilar portal vein. Hepatic growth mediators were measured to 2 months. Results: The decrease in the liver/body weight ratio during the first 7 days which stabilized by day 15, corresponded to parenchymal cell apoptosis and increases in hepatic TGF-β concentration that peaked at 1.4 × baseline at 15 days before returning to control levels by day 30. Variable increases in the concentrations of growth promoters (hepatocyte growth factor, TGF-α and augmenter of liver regeneration) also occurred during the period of hepatocellular apoptosis. Conclusions: The development of hepatic atrophy was associated with changes in TGF-β concentration, and occurred despite increased expression of multiple putative growth promoters. The findings suggest that apoptosis set in motion by TGF-β constrains the amount of hepatocyte proliferation independently from control of liver volume. © 2002 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.
- Published
- 2002
31. Molecular basis of evolutionary loss of the α1,3-galactosyltransferase gene in higher primates
- Author
-
Koike, C, Fung, JJ, Geller, DA, Kannagi, R, Libert, T, Luppi, P, Nakashima, I, Profozich, J, Rudert, W, Sharma, SB, Starzl, TE, Trucco, M, Koike, C, Fung, JJ, Geller, DA, Kannagi, R, Libert, T, Luppi, P, Nakashima, I, Profozich, J, Rudert, W, Sharma, SB, Starzl, TE, and Trucco, M
- Abstract
Galactose-α1,3-galactose (αGal) epitopes, the synthesis of which requires the enzyme product of α1,3-galactosyltransferase (α1,3GT), are sugar chains on the cell surface of most mammalian species. Notable exceptions are higher primates including Old World monkeys, apes, and humans. The αGal-negative species as well as mice with deletion of the α1,3GT gene produce abundant anti-αGal antibodies. The evolutionary loss of αGal epitopes has been attributed to point mutations in the coding region of the gene. Because no transcripts could be found in the higher primate species with Northern blot analysis, a potential alternative explanation has been loss of upstream regulation of the gene. Here, we have demonstrated that the rhesus promoter is functional. More importantly, a variety of full-length transcripts were detected with sensitive PCR-based methods in the tissues of rhesus monkeys, orangutans, and humans. Five crucial mutations were delineated in the coding region of the human and rhesus and three in the orangutan, any one of which could be responsible for inactivation of the α1,3GT gene. Two of the mutations were shared by all three higher primates. These findings, which elucidate the molecular basis for the evolutionary loss of αGal expression, may have implications in medical research.
- Published
- 2002
32. Pediatric liver transplantation in 808 consecutive children: 20-Years experience from a single center
- Author
-
Jain, A, Mazariegos, G, Kashyap, R, Kosmach-Park, B, Starzl, TE, Fung, JJ, Reyes, J, Jain, A, Mazariegos, G, Kashyap, R, Kosmach-Park, B, Starzl, TE, Fung, JJ, and Reyes, J
- Published
- 2002
33. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients
- Author
-
Shapiro, R, Scantlebury, VP, Jordan, ML, Vivas, CA, Jain, A, Hakala, TR, McCauley, J, Johnston, J, Randhawa, P, Fedorek, S, Gray, E, Chesky, A, Dvorchik, I, Donaldson, J, Fung, JJ, Starzl, TE, Shapiro, R, Scantlebury, VP, Jordan, ML, Vivas, CA, Jain, A, Hakala, TR, McCauley, J, Johnston, J, Randhawa, P, Fedorek, S, Gray, E, Chesky, A, Dvorchik, I, Donaldson, J, Fung, JJ, and Starzl, TE
- Published
- 2002
34. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis
- Author
-
Dvorchik, I, Subotin, M, Demetris, AJ, Fung, JJ, Starzl, TE, Wieand, S, Abu-Elmagd, KM, Dvorchik, I, Subotin, M, Demetris, AJ, Fung, JJ, Starzl, TE, Wieand, S, and Abu-Elmagd, KM
- Abstract
This report investigates the influence of liver transplantation and concomitant immunosuppression on the course of progression of inflammatory bowel disease (IBD) and discusses statistical methodology appropriate for such settings. The data on 303 patients who underwent liver transplantation for primary sclerosing cholangitis (PSC) were analyzed using person-time analysis and Cox regression, with the duration of IBD as the time variable and transplantation as a segmented time-dependent covariate, to take into account both posttransplant and pretransplant history of IBD. The need for colectomy and appearance of colorectal cancer were taken as outcome measures. The only significant risk factor in the multivariate model for colectomy was transplantation itself, which increased the risk of colectomy due to intractable disease (Wald statistic; P =. 001). None of the variables available for analysis were found to influence the risk of colon cancer significantly. Graphs showing the dependence of the instantaneous risk of cancer on the time from onset of IBD and its independence from the latter in the case of colectomy are presented. The use of a unique statistical methodology described for the first time in this setting led us to the somewhat surprising conclusion that transplantation and concomitant use of immunosuppression accelerate the progression of IBD. At the same time, transplantation does not affect the incidence of colorectal cancer. These results confirm the findings of some recent studies and can potentially shed new light on the disease pathogenesis.
- Published
- 2002
35. Comparison of the regulatory regions of the α1,3galactosyltransferase gene between murine and porcine species
- Author
-
Koike, C, Friday, R, Fung, JJ, Starzl, TE, Trucco, M, Koike, C, Friday, R, Fung, JJ, Starzl, TE, and Trucco, M
- Published
- 2001
36. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: Increased expression of p21WAF1/Cip1 as a disease marker and the influence of immunosuppressive drugs
- Author
-
Lunz, JG, Contrucci, S, Ruppert, K, Murase, N, Fung, JJ, Starzl, TE, Demetris, AJ, Lunz, JG, Contrucci, S, Ruppert, K, Murase, N, Fung, JJ, Starzl, TE, and Demetris, AJ
- Abstract
Early chronic liver allograft rejection (CR) is characterized by distinctive cytological changes in biliary epithelial cells (BECs) that resemble cellular senescence, in vitro, and precede bile duct loss. If patients suffering from early CR are treated aggressively, the clinical and histopathological manifestations of CR can be completely reversed and bile duct loss can be prevented. We first tested whether the senescence-related p21WAF1/Cip1 protein is increased in BECs during early CR, and whether treatment reversed the expression. The percentage of p21+ BECs and the number of p21+ BECs per portal tract is significantly increased in early CR (26 ± 17% and 3.6 ± 3.1) compared to BECs in normal liver allograft biopsies or those with nonspecific changes (1 ± 1% and 0.1 ± 0.3; P < 0.0001 and P < 0.02), chronic hepatitis C (2 ± 3% and 0.7 ± 1; P < 0.0001 and P < 0.04) or obstructive cholangiopathy (7 ± 7% and 0.7 ± 0.6; P < 0.006 and P = 0.04). Successful treatment of early CR is associated with a decrease in the percentage of p21+ BECs and the number of p21+ BECs per portal tract. In vitro, nuclear p21WAF1/Cip1 expression is increased in large and multinucleated BECs, and is induced by transforming growth factor (TGF)-β. TGF-β1 also increases expression of TGF-β receptor II, causes phosphorylation of SMAD-2 and nuclear translocation of p21WAF1/Cip1, which inhibits BEC growth. Because conversion from cyclosporine to tacrolimus is an effective treatment for early CR, we next tested whether these two immunosuppressive drugs directly influenced BEC growth in vitro. The results show that cyclosporine, but not tacrolimus, stimulates BEC TGF-β1 production, which in turn, causes BEC mito-inhibition and up-regulation of nuclear p21WAF1/Cip1. In conclusion, expression of the senescence-related p21WAF1/Cip1 protein is increased in BECs during early CR and decreases with successful recovery. Replicative senescence accounts for the characteristic BEC cytological alterations used f
- Published
- 2001
37. Causes of death after liver transplantation in 4000 consecutive patients: 2 to 19 year follow-up
- Author
-
Kashyap, R, Jain, A, Reyes, J, Demetris, AJ, Elmagd, KA, Dodson, SF, Marsh, W, Madariaga, V, Mazariegos, G, Geller, D, Bonham, CA, Cacciarelli, T, Fontes, P, Starzl, TE, Fung, JJ, Kashyap, R, Jain, A, Reyes, J, Demetris, AJ, Elmagd, KA, Dodson, SF, Marsh, W, Madariaga, V, Mazariegos, G, Geller, D, Bonham, CA, Cacciarelli, T, Fontes, P, Starzl, TE, and Fung, JJ
- Published
- 2001
38. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: A single center report
- Author
-
Jain, A, Kashyap, R, Dodson, F, Kramer, D, Hamad, I, Khan, A, Eghestad, B, Starzl, TE, Fung, JJ, Jain, A, Kashyap, R, Dodson, F, Kramer, D, Hamad, I, Khan, A, Eghestad, B, Starzl, TE, and Fung, JJ
- Abstract
Background. Tacrolimus (TAC) and mycophenolate mofetil (MMF) are currently approved immunosuppressants for prevention of rejection in liver transplantation (LTx). They have different modes of action and toxicity profiles, but the efficacy and safety of MMF in primary liver transplantation with TAC has not been determined. Methods. An Institutional Review Board-approved, open-label, single-center, prospective randomized trial was initiated to study the efficacy and toxicity of TAC and steroids (double-drug therapy (D)) versus TAC, steroids, and MMF (triple-drug therapy (T)) in primary adult LTx recipients. Both groups of patients were started on the same doses of TAC and steroids. Patients randomized to T also received 1 gm MMF twice a day. Results. Between August 1995 and May 1998, 350 patients were enrolled at a single center-175 in the D and 175 in the T groups. All patients were followed until May 1998, with a mean follow-up of 33.8±9.1 months. Using an intention-to-treat analysis, the 1-, 2-, 3-, and 4-year patient survival was 85.1%, 81.6%, 78.6%, and 75.8%, respectively, for D and 87.4%, 85.4%, 81.3%, and 79.9%, respectively, for T. The 4-year graft survival was 70% for D and 72.1% for T. Although the rate of acute rejection in the first 3 months was significantly lower for T than for D (28% for triple vs. 38.9% for double, P=0.03), the overall rate of rejection for T at the end of 1 year was not significantly lower than for the D (38.9% triple vs. 45.2% double). The median time to the first episode of rejection was 14 days for D versus 24 days for T (P=0.008). During the study period, 38 of 175 patients in D received MMF to control ongoing acute rejection, nephrotoxicity, and/or neurotoxicity. On the other hand, 103 patients in the T discontinued MMF for infection, myelosuppression, and/or gastrointestinal disturbances. The need for corticosteroids was less after 6 months for T and the perioperative need for dialysis was lower with use of MMF. Conclusion. Thi
- Published
- 2001
39. Causes of retransplantation after primary liver transplantation in 4000 consecutive patients: 2 to 19 years follow-up
- Author
-
Kashyap, R, Jain, A, Reyes, J, Demetris, AJ, Elmagd, KA, Dodson, SF, Marsh, W, Madariaga, V, Mazariegos, G, Geller, D, Bonham, CA, Cacciarelli, T, Fontes, P, Starzl, TE, Fung, JJ, Kashyap, R, Jain, A, Reyes, J, Demetris, AJ, Elmagd, KA, Dodson, SF, Marsh, W, Madariaga, V, Mazariegos, G, Geller, D, Bonham, CA, Cacciarelli, T, Fontes, P, Starzl, TE, and Fung, JJ
- Published
- 2001
40. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years
- Author
-
Jain, A, Demetris, AJ, Kashyap, R, Blakomer, K, Ruppert, K, Khan, A, Rohal, S, Starzl, TE, Fung, JJ, Jain, A, Demetris, AJ, Kashyap, R, Blakomer, K, Ruppert, K, Khan, A, Rohal, S, Starzl, TE, and Fung, JJ
- Abstract
Tacrolimus has proven to be a potent immunosuppressive agent in liver transplantation (LT). Its introduction has led to significantly less frequent and severe acute rejection. Little is known about the rate of chronic rejection (CR) in primary LT using tacrolimus therapy. The aim of the present study is to examine the long-term incidence of CR, risk factors, prognostic factors, and outcome after CR. The present study evaluated the development of CR in 1,048 consecutive adult primary liver allograft recipients initiated and mostly maintained on tacrolimus-based immunosuppressive therapy. They were evaluated with a mean follow-up of 77.3 ± 14.7 months (range, 50.7 to 100.1 months). To assess the impact of primary diagnosis on the rate and outcome of CR, the population was divided into 3 groups. Group I included patients with hepatitis C virus (HCV)- or hepatitis B virus (HBV)-induced cirrhosis (n = 312); group II included patients diagnosed with primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), or autoimmune hepatitis (AIH; n = 217); and group III included patients with all other diagnoses (n = 519). Overall, 32 of 1,048 patients (3.1%) developed CR. This represented 13 (4.1%), 12 (5.5%), and 7 patients (1.3%) in groups I, II, and III, respectively. The relative risk for developing CR was 3.2 times greater for group I and 4.3 times greater for group II compared with group III. This difference was statistically significant (P = .004). The incidence of acute rejection and total number of acute rejection episodes were significantly greater in patients who developed CR compared with those who did not (P < .0001). Similarly, the mean donor age for CR was significantly older than for patients without CR (43.0 v 36.2 years; P = .02). Thirteen of the 32 patients (40.6%) who developed CR retained their original grafts for a mean period of 54 ± 25 months after diagnosis. Seven patients (21.9%) underwent re-LT, and 12 patients (38.3%) died. Serum bilirubin l
- Published
- 2001
41. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: Complete report on 350 primary adult liver transplantations
- Author
-
Jain, A, Kashyap, R, Kramer, D, Dodson, F, Hamad, I, Starzl, TE, Fung, JJ, Jain, A, Kashyap, R, Kramer, D, Dodson, F, Hamad, I, Starzl, TE, and Fung, JJ
- Published
- 2001
42. Donor bone marrow infusion in liver recipients: Effect on the occurrence of acute cellular rejection
- Author
-
Rao, AS, Dvorchik, I, Dodson, F, Abu-Elmagd, K, Schaefer, AT, Ostrowski, L, Valenti, M, Zeevi, A, Kuddus, R, Starzl, TE, Fung, JJ, Rao, AS, Dvorchik, I, Dodson, F, Abu-Elmagd, K, Schaefer, AT, Ostrowski, L, Valenti, M, Zeevi, A, Kuddus, R, Starzl, TE, and Fung, JJ
- Published
- 2001
43. Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression
- Author
-
Chakrabarti, P, Wong, HY, Toyofuku, A, Scantlebury, VP, Jordan, ML, Vivas, C, Jain, AB, McCauley, J, Johnston, J, Randhawa, PS, Hakala, TR, Simmons, RL, Fung, JJ, Starzl, TE, Shapiro, R, Chakrabarti, P, Wong, HY, Toyofuku, A, Scantlebury, VP, Jordan, ML, Vivas, C, Jain, AB, McCauley, J, Johnston, J, Randhawa, PS, Hakala, TR, Simmons, RL, Fung, JJ, Starzl, TE, and Shapiro, R
- Published
- 2001
44. Liver transplantation for alcoholic cirrhosis: Long term follow-up and impact of disease recurrence
- Author
-
Bellamy, COC, DiMartini, AM, Ruppert, K, Jain, A, Dodson, F, Torbenson, M, Starzl, TE, Fung, JJ, Demetris, AJ, Bellamy, COC, DiMartini, AM, Ruppert, K, Jain, A, Dodson, F, Torbenson, M, Starzl, TE, Fung, JJ, and Demetris, AJ
- Abstract
Background. Alcoholic liver disease has emerged as a leading indication for hepatic transplantation, although it is a controversial use of resources. We aimed to examine all aspects of liver transplantation associated with alcohol abuse. Methods. Retrospective cohort analysis of 123 alcoholic patients with a median of 7 years follow-up at one center. Results. In addition to alcohol, 43 (35%) patients had another possible factor contributing to cirrhosis. Actuarial patient and graft survival rates were, respectively, 84% and 81% (1 year); 72% and 66% (5 years); and 63% and 59% (7 years). After transplantation, 18 patients (15%) manifested 21 noncutaneous de novo malignancies, which is significantly more than controls (P=0.0001); upper aerodigestive squamous carcinomas were over-represented (P=0.03). Thirteen patients had definitely relapsed and three others were suspected to have relapsed. Relapse was predicted by daily ethanol consumption (P=0.0314), but not by duration of pretransplant sobriety or explant histology. No patient had alcoholic hepatitis after transplantation and neither late onset acute nor chronic rejection was significantly increased. Multiple regression analyses for predictors of graft failure identified major biliary/vascular complications (P=0.01), chronic bile duct injury on biopsy (P=0.002), and pericellular fibrosis on biopsy (P=0.05); graft viral hepatitis was marginally significant (P=0.07) on univariate analysis. Conclusions. Alcoholic liver disease is an excellent indication for liver transplantation in those without coexistent conditions. Recurrent alcoholic liver disease alone is not an important cause of graft pathology or failure. Potential recipients should be heavily screened before transplantation for coexistent conditions (e.g., hepatitis C, metabolic diseases) and other target-organ damage, especially aerodigestive malignancy, which are greater causes of morbidity and mortality than is recurrent alcohol liver disease.
- Published
- 2001
45. Kidney transplantation with bone marrow augmentation: Five-year outcomes
- Author
-
Shapiro, R, Rao, AS, Corry, RJ, Valenti, M, Zeevi, A, Jordan, ML, Scantlebury, VP, Vivas, CA, Jain, A, McCauley, J, Randhawa, P, Gray, EA, Dvorchik, I, McMichael, J, Fung, JJ, Starzl, TE, Shapiro, R, Rao, AS, Corry, RJ, Valenti, M, Zeevi, A, Jordan, ML, Scantlebury, VP, Vivas, CA, Jain, A, McCauley, J, Randhawa, P, Gray, EA, Dvorchik, I, McMichael, J, Fung, JJ, and Starzl, TE
- Published
- 2001
46. An Analysis of Early Renal Transplant Protocol Biopsies - the High Incidence of Subclinical Tubulitis
- Author
-
Shapiro, R, Randhawa, P, Jordan, ML, Scantlebury, VP, Vivas, C, Jain, A, Corry, RJ, McCauley, J, Johnston, J, Donaldson, J, Gray, EA, Dvorchik, I, Hakala, TR, Fung, JJ, Starzl, TE, Shapiro, R, Randhawa, P, Jordan, ML, Scantlebury, VP, Vivas, C, Jain, A, Corry, RJ, McCauley, J, Johnston, J, Donaldson, J, Gray, EA, Dvorchik, I, Hakala, TR, Fung, JJ, and Starzl, TE
- Abstract
To investigate the possibility that we have been underestimating the true incidence of acute rejection, we began to perform protocol biopsies after kidney transplantation. This analysis looks at the one-week biopsies. Between March 1 and October 1, 1999, 100 adult patients undergoing cadaveric kidney or kidney/pancreas transplantation, or living donor kidney transplantation, underwent 277 biopsies. We focused on the subset of biopsies in patients without delayed graft function (DGF) and with stable or improving renal function, who underwent a biopsy 8.2 ± 2.6 d (range 3-18 d) after transplantation (n = 28). Six (21%) patients with no DGF and with stable or Improving renal function had borderline histopathology, and 7 (25%) had acute tubulitis on the one-week biopsy. Of the 277 kidney biopsies, there was one (0.4%) serious hemorrhagic complication, in a patient receiving low molecular weight heparin; she ultimately recovered and has normal renal function. Her biopsy showed Banff 1B tubulitis. In patients with stable or improving renal allograft function early after transplantation, subclinical tubulitis may be present in a substantial number of patients. This suggests that the true incidence of rejection may be higher than is clinically appreciated.
- Published
- 2001
47. Isolation of the regulatory regions and genomic organization of the porcine α1,3-galactosyltransferase gene1
- Author
-
Koike, C, Friday, RP, Nakashima, I, Luppi, P, Fung, JJ, Rao, AS, Starzl, TE, Trucco, M, Koike, C, Friday, RP, Nakashima, I, Luppi, P, Fung, JJ, Rao, AS, Starzl, TE, and Trucco, M
- Abstract
Background. α1,3-galactosyltransferase (α1,3GT) is an enzyme that produces carbohydrate chains termed αGal epitopes found in most mammals, although some species of higher primates, including human, are notable exceptions. The evolutionary origin of the lost α1,3GT enzyme activity is not yet known, although it has been suggested that the promoter activity of this gene in the ancestors of higher primates was inactivated. Methods. We used 5'-or 3'-RACE, GenomeWalking, reverse transcriptase polymerase chain reaction (RT-PCR) and dual Luciferase reporter assay for identification of the full-length cDNA, which includes the transcription initiation site and the promoter region of porcine α1,3GT gene. Results. The region around exon 1 is guanine and cytosine (GC)-rich (about 70%), comprising a CpG island spanning more than 1.5 kbp. The 5'-flanking region of exon 1 contains multiple transcription factor consensus motifs, including GC-box, SP1, AP2, and GATA-box sites, in the absence of TATA or CAAT-box sequences. The entire gene consists of three 5' noncoding and six coding region exons spanning more than 52 kbp. Detailed analysis of α1,3GT transcripts revealed two major alternative splicing patterns in the 5'-untranslated region (5'-UTR) and evidence for minor splicing activity that occurs in a tissue-specific manner. Interspecies comparison of 5'-UTR shows minimal homology between porcine and routine sequences except for exon 2, which suggests that the regulatory regions differ among species. Conclusions. These observations have important implications for experiments involving genetic manipulation of the α1,3GT gene in transgenic animals in terms of promoter utilization, and particularly in genetically engineering cells for the animal cloning technology by nuclear transfer.
- Published
- 2000
48. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: Long-term follow-up and evaluation of features for histopathological staging
- Author
-
Blakolmer, K, Jain, A, Ruppert, K, Gray, E, Duquesnoy, R, Murase, N, Starzl, TE, Fung, JJ, Demetris, AJ, Blakolmer, K, Jain, A, Ruppert, K, Gray, E, Duquesnoy, R, Murase, N, Starzl, TE, Fung, JJ, and Demetris, AJ
- Abstract
Background: Predisposing factors, long-term occurrence, and histopathological changes associated with recovery or progression to allograft failure from chronic rejection (CR) were studied in adult patients treated primarily with tacrolimus. Methods: CR cases were identified using stringent criteria applied to a retrospective review of computerized clinicopathological data and slides. Results: After 1973 days median follow- up, 35 (3.3%) of 1049 primary liver allograft recipients first developed CR between 16 and 2532 (median 242) days. The most significant risk factors for CR were the number (P<0.001) and histological severity (P<0.005) of acute rejection episodes and donor age >40 years (P<0.03). Other demographic and matching parameters were not associated with CR in this cohort. Ten patients died with, but not of, CR. Eight required retransplantation because of CR at a median of 268 days. Ten resolved either histologically or by normalization of liver injury tests over a median of 548 days. CR persisted for 340 to 2116 days in the remaining seven patients. More extensive bile duct loss (P<0.01), small arterial loss (p<0.03), foam cell clusters (P<0.01) and higher total bilirubin (p<0.02) and aspartate aminotransferase (p<0.03) were associated with allograft failure from CR. Conclusions: Early chronic liver allograft rejection is potentially reversible and a combination of histological, clinical and laboratory data can be use to stage CR. Unique immunological and generative properties of liver allografts, which lead to low incidence and reversibility of early CR, can provide insights into transplantation biology.
- Published
- 2000
49. Posttransplant lymphoproliferative disorders in small bowel allograft recipients
- Author
-
Nalesnik, M, Jaffe, R, Reyes, J, Mazariegos, G, Fung, JJ, Starzl, TE, Abu-Elmagd, K, Nalesnik, M, Jaffe, R, Reyes, J, Mazariegos, G, Fung, JJ, Starzl, TE, and Abu-Elmagd, K
- Published
- 2000
50. Future of transplantation (including xenografting)
- Author
-
Ayers, SM, Grenvik, A, Holbrook, PR, Shoemaker, WC, Fung, JJ, Rao, A, Molmenti, E, Dodson, F, Starzl, TE, Ayers, SM, Grenvik, A, Holbrook, PR, Shoemaker, WC, Fung, JJ, Rao, A, Molmenti, E, Dodson, F, and Starzl, TE
- Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.